Uncategorized
Supreme Court ruling accelerates availability of biosimilars
The Supreme Court issued a unanimous ruling today that will accelerate the pace at which biosimilars can be made available to the public.The court ruled biosimilar manufacturers do not need to wait an extra 6 months after FDA approval to market their agents, provided the standard exclusivity period for the biosimilar’s reference product has expired.